Application of fragment screening by X-ray crystallography to β-secretase

Journal of Medicinal Chemistry

Volumn 50, Issue 6, 2007, Pages 1116-1123

  Murray, Christopher W ^a   Callaghan, Owen ^a   Chessari, Gianni ^a   Cleasby, Anne ^a   Congreve, Miles ^a   Frederickson, Martyn ^a   Hartshorn, Michael J ^a   McMenamin, Rachel ^a   Patel, Sahil ^a   Wallis, Nicola ^a  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOQUINOLINE; AMINOPYRIDINE DERIVATIVE; ASPARTIC PROTEINASE; BETA SECRETASE; BETA SECRETASE INHIBITOR; HETEROCYCLIC AMINE; HYDROXYL GROUP; PIPERIDINE DERIVATIVE;

ARTICLE; DRUG BINDING SITE; DRUG DESIGN; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; HIGH THROUGHPUT SCREENING; PROTEIN MOTIF; X RAY CRYSTALLOGRAPHY;

AMINOQUINOLINES; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ENDOPEPTIDASES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; PIPERIDINES; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECOMBINANT PROTEINS;

EID: 33947612966     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0611962     Document Type: Article

References (68)

1. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297, 353-356.
2. Sinha, S.; Lieberburg, I. Cellular mechanisms of beta-amyloid production and secretion. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 11049-11053.
3. Hussain, I.; Powell, D.: Howlett, D. R.; Tew, D. G.; Meek, T. D.; Chapman, C.; Gloger, I. S.; Murphy, K. E.; Southan, C. D.; Ryan, D. M.; Smith, T. S.; Simmons, D. L.; Walsh, F. S.; Dingwall, C.; Christie, G. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol. Cell Neurosci. 1999, 14, 419-427.
4. Lin, X.; Koelsch, G.; Wu, S.; Downs, D.; Dashti, A.; Tang, J. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 1456-1460.
5. Sinha, S.; Anderson, J. P.; Barbour, R.; Basi, G. S.; Caccavello, R.; Davis, D.; Doan, M.; Dovey, H. F.; Frigon, N.; Hong, J.; Jacobson-Croak, K.; Jewett, N.; Keim, P.; Knops, J.; Lieberburg, I.; Power, M.; Tan, H.; Tatsuno, G.; Tung, J.; Schenk, D.; Seubert, P.; Suomensaari, S. M.; Wang, S.; Walker, D.; Zhao, J.; McConlogue, L.; John, V. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999, 402, 537-540.
6. Vassar, R.; Bennett, B. D.; Babu-Khan, S.; Kahn, S.; Mendiaz, E. A.; Denis, P.; Teplow, D. B.; Ross, S.; Amarante, P.; Loeloff, R.; Luo, Y.; Fisher, S.; Fuller, J.; Edenson, S.; Lile, J.; Jarosinski, M. A.; Biere, A. L.; Curran, E.; Burgess, T.; Louis, J. C.; Collins, F.; Treanor, J.; Rogers, G.; Citron, M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286, 735-741.
7. Willem, M.; Garratt, A. N.; Novak, B.; Citron, M.; Kaufmann, S.; Rittger, A.; DeStrooper, B.; Saftig, P.; Birchmeier, C.; Haass, C. Control of peripheral nerve myelination by the beta-secretase BACE1. Science 2006, 314, 664-666.
8. Bursavich, M. G.; Rich, D. H. Designing nonpeptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. J. Med. Chem. 2002, 45, 541-558.
9. Wood, J. M.; Maibaum, J.; Rahuel, J.; Grutter, M. G.; Cohen, N. C.; Rasetti, V.; Ruger, H.; Goschke, R.; Stutz, S.; Fuhrer, W.; Schilling, W.; Rigollier, P.; Yamaguchi, Y.; Cumin, F.; Baum, H. P.; Schnell, C. R.; Herold, P.; Mah, R.; Jensen, C.; O'Brien, E.; Stanton, A.; Bedigian, M. P. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. 2003, 308, 698-705.
10. Rahuel, J.; Rasetti, V.; Maibaum, J.; Rueger, H.; Goschke, R.; Cohen, N. C.; Stutz, S.; Cumin, F.; Fuhrer, W.; Wood, J. M.; Grutter, M. G. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem. Biol 2000, 7, 493-504.
11. Culler, R.; Binggeli, A.; Breu, V.; Bur, D.; Fischli, W.; Hirth, G.; Jenny, C.; Kansy, M.; Montavon, F.; Muller, M.; Oefner, C.; Stadler, H.; Vieira, E.; Wilhelm, M.; Wostl, W.; Marki, H. P. Piperidine-renin inhibitors compounds with improved physicochemical properties. Bioorg. Med. Chem. Lett. 1999, 9, 1403-1408.
12. Oefner, C.; Binggeli, A.; Breu, V.; Bur, D.; Clozel, J. P.; D'Arcy, A.; Dorn, A.; Fischli, W.; Gruninger, F.; Guller, R.; Hirth, G.; Marki, H.; Mathews, S.; Her, M.; Ridley, R. G.; Stadler, H.; Vieira, E.; Wilhelm, M.; Winkler, F.; Wostl, W. Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases? Chem. Biol 1999, 6, 127-131.
13. Vieira, E.; Binggeli, A.; Breu, V.; Bur, D.; Fischli, W.; Guller, R.; Hirth, G.; Marki, H. P.; Muller, M.; Oefner, C.; Scalone, M.; Stadler, H.; Wilhelm, M.; Wostl, W. Substituted piperidines-highly potent renin inhibitors due to induced fit adaptation of the active site. Bioorg. Med. Chem. Lett. 1999, 9, 1397-1402.
14. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
15. John, V.; Beck, J. P.; Bienkowski, M. J.; Sinha, S.; Heinrikson, R. L. Human beta-secretase (BACE) and BACE inhibitors. J. Med. Chem. 2003, 46, 4625-4630.
16. Cumming, J. N.; Iserloh, U.; Kennedy, M. E. Design and development of BACE-1 inhibitors. Curr. Opin. Drug Discovery Dev. 2004, 7, 536-556.
17. Brady, S. F.; Singh, S.; Crouthamel, M. C.; Holloway, M. K.; Coburn, C. A.; Garsky, V. M.; Bogusky, M.; Pennington, M. W.; Vacca, J. P.; Hazuda, D.; Lai, M. T. Rational design and synthesis of selective BACE-1 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 601-604.
18. Chen, S. H.; Lamar, J.; Guo, D.; Kohn, T.; Yang, H. C.; McGee, J.; Timm, D.; Erickson, J.; Yip, Y.; May, P.; McCarthy, J. P3 cap modified Phe*-Ala series BACE inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 245-250.
19. Ghosh, A. K.; Bilcer, G.; Harwood, C.; Kawahama, R.; Shin, D.; Hussain, K. A.; Hong, L.; Loy, J. A.; Nguyen, C.; Koelsch, G.; Ermolieff, J.; Tang, J. Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase). J. Med. Chem. 2001, 44, 2865-2868.
20. Ghosh, A. K.; Devasamudram, T.; Hong, L.; DeZutter, C.; Xu, X.; Weerasena, V.; Koelsch, G.; Bilcer, G.; Tang, J. Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (beta-secretase). Bioorg. Med. Chem. Lett. 2005, 15, 15-20.
21. Hanessian, S.; Yun, H.; Hou, Y.; Yang, G.; Bayrakdarian, M.; Therrien, E.; Moitessier, N.; Roggo, S.; Veenstra, S.; Tintelnot-Blomley, M.; Rondeau, J. M.; Ostermeier, C.; Strauss, A.; Ramage, P.; Paganetti, P.; Neumann, U.; Betschart, C. Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. J. Med. Chem. 2005, 48, 5175-5190.
22. Horn, R. K.; Fang, L. Y.; Mamo, S.; Tung, J. S.; Guinn, A. C.; Walker, D. E.; Davis, D. L.; Gailunas, A. F.; Thorsett, E. D.; Sinha, S.; Knops, J. E.; Jewett, N. E.; Anderson, J. P.; John, V. Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase. J. Med. Chem. 2003, 46, 1799-1802.
23. Horn, R. K.; Gailunas, A. F.; Mamo, S.; Fang, L. Y.; Tung, J. S.; Walker, D. E.; Davis, D.; Thorsett, E. D.; Jewett, N. E.; Moon, J. B.; John, V. Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human beta-secretase. J. Med. Chem. 2004, 47, 158-164.
24. Hu, B.; Fan, K. Y.; Bridges, K.; Chopra, R.; Lovering, F.; Cole, D.; Zhou, P.; Ellingboe, J.; Jin, G.; Cowling, R.; Bard, J. Synthesis and SAR of bis-statine based peptides as BACE 1 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 3457-3460.
25. Lamar, J.; Hu, J.; Bueno, A. B.; Yang, H. C.; Guo, D.; Copp, J. D.; McGee, J.; Gitter, B.; Timm, D.; May, P.; McCarthy, J.; Chen, S. H. Phe*-Ala-based pentapeptide mimetics are BACE inhibitors: P2 and P3 SAR. Bioorg. Med. Chem. Lett. 2004, 14, 239-243.
26. Yang, W.; Lu, W.; Lu, Y.; Zhong, M.; Sun, J.; Thomas, A. E.; Wilkinson, J. M.; Fucini, R. V.; Lam, M.; Randal, M.; Shi, X. P.; Jacobs, J. W.; McDowell, R. S.; Gordon, E. M.; Ballinger, M. D. Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1. J. Med. Chem. 2006, 49, 839-842.
27. Clark, D. E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci. 1999, 88, 815-821.
28. Stachel, S. J.; Coburn, C. A.; Steele, T. G.; Jones, K. G.; Loutzenhiser, E. F.; Gregro, A. R.; Rajapakse, H. A.; Lai, M. T.; Crouthamel, M. C.; Xu, M.; Tugusheva, K.; Lineberger, J. E.; Pietrak, B. L.; Espeseth, A. S.; Shi, X. P.; Chen-Dodson, E.; Holloway, M. K.; Munshi, S.; Simon, A. J.; Kuo, L.; Vacca, J. P. Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). J. Med. Chem. 2004, 47, 6447-6450.
29. Coburn, C. A.; Stachel, S. J.; Li, Y. M.; Rush, D. M.; Steele, T. G.; Chen-Dodson, E.; Holloway, M. K.; Xu, M.; Huang, Q.; Lai, M. T.; DiMuzio, J.; Crouthamel, M. C.; Shi, X. P.; Sardana, V.; Chen, Z.; Munshi, S.; Kuo, L.; Makara, G. M.; Annis, D. A.; Tadikonda, P. K.; Nash, H. M.; Vacca, J. P.; Wang, T. Identification of a small molecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases. J. Med. Chem. 2004, 47, 6117-6119.
30. Garino, C.; Pietrancosta, N.; Laras, Y.; Moret, V.; Rolland, A.; Quelever, G.; Kraus, J. L. BACE-1 inhibitory activities of new substituted phenyl-piperazinecoupled to various heterocycles: chromene, coumarin and quinoline. Bioorg. Med. Chem. Lett. 2006, 16, 1995-1999.
31. Huang, D.; Luthi, U.; Kolb, P.; Cecchini, M.; Barberis, A.; Caflisch, A. In silico discovery of beta-secretase inhibitors. J. Am. Chem. Soc. 2006, 128, 5436-5443.
32. Huang, D.; Luthi, U.; Kolb, P.; Edler, K.; Cecchini, M.; Audetat, S.; Barberis, A.; Caflisch, A. Discovery of cell-permeable nonpeptide inhibitors of beta-secretase by high-throughput docking and continuum electrostatics calculations. J. Med. Chem. 2005, 48, 5108-5111.
33. Carr, R.; Jhoti, H. Structure-based screening of low-affinity compounds. Drug Discovery Today 2002, 7, 522-527.
34. Lesuisse, D.; Lange, G.; Deprez, P.; Benard, D.; School, B.; Delettre, G.; Marquette, J. P.; Broto, P.; Jean-Baptiste, V.; Eichet, P.; Sarubbi, E.; Mandine, E. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. J. Med. Chem. 2002, 45, 2379-2387.
35. Hann, M. M.; Leach, A. R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
36. Carr, R. A. E.; Congreve, M.; Murray, C. W.; Rees, D. C. Fragment-based lead discovery: leads by design. Drug Discovery Today 2005, 10, 987-992.
37. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 2004, 9, 430-431.
38. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9997-10002.
39. Boehm, H. J.; Boehringer, M.; Bur, D.; Gmuender, H.; Huber, W.; Klaus, W.; Kostrewa, D.; Kuehne, H.; Luebbers, T.; Meunier-Keller, N.; Mueller, F. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem. 2000, 43, 2664-2674.
40. Bosch, J.; Robien, M. A.; Mehlin, C.; Boni, E.; Riechers, A.; Buckner, F. S.; Van Voorhis, W. C.; Myler, P. J.; Worthey, E. A.; Detitta, G.; Luft, J. R.; Lauricella, A.; Guide, S.; Anderson, L. A.; Kalyuzhniy, O.; Neely, H. M.; Ross, J.; Earnest, T. N.; Soltis, M.; Schoenfeld, L.; Zucker, F.; Merritt, E. A.; Fan, E.; Verlinde, C. L.; Hol, W. G. Using Fragment Cocktail Crystallography To Assist Inhibitor Design of Trypanosoma bruceiNucleoside 2- Deoxyribosyltransferase. J. Med. Chem. 2006, 49, 5939-5946.
41. Nienaber, V. L.; Richardson, P. L.; Klighofer, V.; Bouska, J. J.; Giranda, V. L.; Greer, J. Discovering novel ligands for macromolecules using X-ray cristallographic screening. Nat. Biotechnol. 2000, 18, 1105-1108.
42. Sanders, W. J.; Nienaber, V. L.; Lerner, C. G.; McCall, J. O.; Merrick, S. M.; Swanson, S. J.; Harlan, J. E.; Stoll, V. S.; Stamper, G. F.; Betz, S. F.; Condroski, K. R.; Meadows, R. P.; Severin, J. M.; Walter, K. A.; Magdalinos, P.; Jakob, C. G.; Wagner, R.; Beutel, B. A. Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization. J. Med. Chem. 2004, 47, 1709-1718.
43. Verlinde, C. L. M. J.; Kim, H.; Bernstein, B. E.; Mande, S. C.; Hol, W. G. J. Antitrypanosomiasis drug development based on structures of glycolitic enzymes. In Structure-based drug design; Veerapandian, P., Ed.; Marcel Dekker, Inc.: New York, 1997; pp 365-394.
44. Gill, A. L.; Frederickson, M.; Cleasby, A.; Woodhead, S. J.; Carr, M. G.; Woodhead, A. J.; Walker, M. T.; Congreve, M. S.; Devine, L. A.; Tisi, D.; O'Reilly, M.; Seavers, L. C.; Davis, D. J.; Curry, J.; Anthony, R.; Padova, A.; Murray, C. W.; Carr, R. A.; Jhoti, H. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. J. Med. Chem. 2005, 48, 414-426.
45. Hartshorn, M. J.; Murray, C. W.; Cleasby, A.; Frederickson, M.; Tickle, I. J.; Jhoti, H. Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. 2005, 48, 403-413.
46. Howard, N.; Abell, C.; Blakemore, W.; Chessari, G.; Congreve, M.; Howard, S.; Jhoti, H.; Murray, C. W.; Seavers, L. C.; van Montfort, R. L. Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. J. Med. Chem. 2006, 49, 1346-1355.
47. Patel, S.; Vuillard, L.; Cleasby, A.; Murray, C. W.; Yon, J. Apo and inhibitor complex structures of BACE (beta-secretase). J. Mol. Biol. 2004, 343, 407-416.
48. Mooij, W. T.; Hartshorn, M. J.; Tickle, I. J.; Sharff, A. J.; Verdonk, M. L.; Jhoti, H. Automated protein-ligand crystallography for structure-based drug design. ChemMedChem. 2006, 1, 827-838.
49. Hong, L.; Koelsch, G.; Lin, X.; Wu, S.; Terzyan, S.; Ghosh, A. K.; Zhang, X. C.; Tang, J. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 2000, 290, 150-153.
50. Turner, R. T., III; Koelsch, G.; Hong, L.; Castanheira, P.; Ermolieff, J.; Ghosh, A. K.; Tang, J. Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design. Biochemistry 2001, 40, 10001-10006.
51. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A 'rule of three' for fragment-based lead discovery? Drug Discovery Today 2003, 8, 876-877.
52. Powell, N. A.; Clay, E. H.; Holsworth, D. D.; Bryant, J. W.; Ryan, M. J.; Jalaie, M.; Edmunds, J. J. Benzyl ether structure-activity relationships in a series of ketopiperazine-based renin inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 4713-4716.
53. Jones, G.; Willett, P.; Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 1995, 245, 43-53.
54. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
55. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions .1. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput.-Aided Mol. Des. 1997, 11, 425-445.
56. Verdonk, M. L.; Cole, J. C.; Hartshorn, M.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623.
57. Bursavich, M. G.; Rich, D. H. Designing nonpeptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. J. Med. Chem. 2002, 45, 541-558.
58. Carr, R. A.; Congreve, M.; Murray, C. W.; Rees, D. C. Fragment-based lead discovery: leads by design. Drug Discovers Today 2005, 10, 987-992.
59. After the submission of this paper, Cole et al. described the use of acylguanidines as inhibitors of BACE-1. These compounds exploit the same binding motif described in this work. Cole, D. C.; Manas, E. S.; Stock, J. R.; Condon, J. S.; Jennings, L. D.; Aulabaugh, A.; Chopra, R.; Cowling, R.; Ellingboe, J. W.; Fan, K. Y.; Harrison, B. L.; Hu, Y.; Jacobsen, S.; Jin, G.; Lin, L.; Lovering, F. E.; Malamas, M. S.; Stahl, M. L.; Strand, J.; Sukhdeo, M. N.; Svenson, K.; Turner, M. J.; Wagner, E.; Wu, J.; Zhou, P.; Bard, J. Acylguanidines as small-molecule beta-secretase inhibitors. J. Med. Chem. 2006, 49, 6158-6161.
60. There have also been two recent patent applications containing aminopyridines and their potential use as BACE-1 inhibitors, (a) Coburn, C. A.; Holloway, M. K.; Stachel, S. J. 2-aminopyridines compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease. PCT Int. Appl. WO 2006060109, 2006.
61. (b) Albert, J. S.; Callaghan, O.; Campbell, J.; Carr, R. A. E.; Chessari, G.; Cowan, S.; Congreve, M. S.; Edwards, P.; Frederickson, M.; Murray, C. W.; Patel, S. Substituted aminopyridines and uses thereof. PCT Int. Appl. WO2006065204, 2006.
62. Leslie, A. G. W.; Brick, P.; Wonacott, A. MOSFLM. Daresbury Lab. Inf. Quart. Protein Crystallogr. 2004, 18, 33-39.
63. Collaborative Computational Project, N. 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. 1994, D50, 760-763.
64. Hartshorn, M. J. AstexViewer: a visualisation aid for structure-based drug design. J. Comput.-Aided Mol. Des. 2002, 16, 871-881.
65. Winn, M. D.; Isupov, M. N.; Murshudov, G. N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr. D: Biol. Crystallogr. 2001, 57, 122-133.
66. Park, H.; Lee, S. Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design. J. Am. Chem. Soc. 2003, 125, 16416-16422.
67. Polgar, T.; Keseru, G. M. Virtual screening for beta-secretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228. J. Med. Chem. 2005, 48, 3749-3755.
68. Watson, P.; Verdonk, M. L.; Hartshorn, M. J. A web-based platform for virtual screening. J. Mol. Graph. Model. 2003, 22, 71-82.